Contact: Vicki Cohn, (914) 740-2156, email@example.com
First Comprehensive Guidelines for Managing Anaplastic Thyroid Cancer Published in Thyroid Journal
New Rochelle, NY, November 7, 2012—Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The Guidelines, prepared by the American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce, are available free online on the Thyroid website.
Robert C. Smallridge, MD, Chair of the ATA Task Force, from the Mayo Clinic, Jacksonville, FL, and coauthors of the "American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer" emphasize the importance of rapid diagnosis and evaluation of this aggressive tumor, establishing treatment goals, and employing a multidisciplinary team approach for optimal patient management. The comprehensive Guidelines cover recommended approaches to treatment including surgery, radiotherapy, systemic therapy, and supportive care. They also offer guidance on managing patients with advanced/metastatic disease, surveillance and long-term monitoring, palliative care options, and ethical issues including end-of-life care.
"The American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer is a remarkable and comprehensive document that distills the literature and taskforce expertise into a useful guide for providers of patients with this aggressive cancer. The focused therapeutic approaches, as well as the inclusion of palliative care and ethical issues into this document, is a real advance for our field,” says Bryan R. Haugen, MD, President of the ATA and Professor of Medicine and Pathology, Head, Division of Endocrinology, Metabolism & Diabetes, Mary Rossick Kern and Jerome H. Kern Chair in Endocrine Neoplasms Research, University of Colorado School of Medicine.
“The Anaplastic Thyroid Cancer Guidelines are a unique contribution to the endocrine literature,” says Charles H. Emerson, MD, Editor-in-Chief of Thyroid and Professor Emeritus of Medicine at the University of Massachusetts School of Medicine. “The Guidelines demand to be read now, not learned during the emergency that is anaplastic thyroid cancer.”
About the Journal
Thyroid, the Official Journal of the American Thyroid Association is an authoritative peer-reviewed journal published monthly in print and online. The Journal publishes original articles and timely reviews that reflect the rapidly advancing changes in our understanding of thyroid physiology and pathology, from the molecular biology of the cell to clinical management of thyroid disorders. Complete tables of content and a sample issue may be viewed online on the Thyroid website.
About the Society
The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international membership medical society with over 1,600 members from 43 countries around the world. Celebrating its 89th anniversary, ATA delivers its mission through several key endeavors: the publication of highly regarded monthly journals, Thyroid, Clinical Thyroidology, and Clinical Thyroidology for Patients; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public, and patient educational programs; and the development of guidelines for clinical management of thyroid disease. The ATA has extensive online information at available on their website (http://www.thyroid.org) on thyroid disease for patients in both English and Spanish and serves as the clinical resource for patients and the public who look for reliable information on the Internet.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Diabetes Technology & Therapeutics, Journal of Women’s Health, and Metabolic Syndrome and Related Disorders. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.